OBI Enters License Agreement with Odeon for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

1.Date of occurrence of the event:2022/02/22 2.Counterparty to the contract or commitment: Odeon Therapeutics (Hong Kong) Limited (hereinafter referred to as “ Odeon”) 3.Relationship with the Company: None 4.Starting and ending dates (or rescission date) of the contract or commitment: 2022/02/22 5.Major content (not applicable where rescinded): (1)OBI Pharma enters license agreement with Odeon Therapeutics […]